Core Insights - The company reported that its performance reached a low point in Q3 due to challenges from healthcare policy adjustments and pharmaceutical procurement [2] - Since the end of Q3, the company has implemented various measures leading to a significant recovery and growth in performance [2] Medical Sector - The medical segment has effectively responded to healthcare payment challenges through proactive discipline construction and cost structure optimization [2] - New hospital construction and the development of non-medical insurance-dependent disciplines have enhanced regional competitiveness and service capabilities [2] - Overall, the market share and profits of medical institutions have steadily increased [2] Pharmaceutical Sector - The pharmaceutical segment, led by "Duyiwei Pharmaceutical," has seen fundamental improvements in performance since September through comprehensive optimization of sales, products, and markets [2] - The introduction of strategic investors is driving Duyiwei's transition into a national pharmaceutical group [2] Future Outlook - The company plans to deepen its "health technology" positioning through continuous asset injections [2] - There is a focus on exploring innovative business segments that represent new productive forces to build new growth engines for the future [2]

Core Viewpoint - The company reported a loss in the first three quarters due to changes in centralized procurement prices and transitional market acceptance issues, but there are signs of recovery in sales since September [1] Group 1: Financial Performance - The company experienced a loss in the first three quarters of the year due to reduced profit margins from centralized procurement price changes and market acceptance during the transition period [1] - Sales strategies have been adjusted to improve performance, focusing on refined management of the agent market and increasing coverage of grassroots medical institutions [1] Group 2: Sales and Marketing Strategies - The company is guiding agents to switch to larger specification products and providing greater profit margins to enhance sales [1] - Future plans include lowering sales commission rates, expanding into the retail market, and strengthening e-commerce channel development to boost sales capabilities [1] Group 3: Operational Improvements - The company aims to inject new product resources into its pharmaceutical segment through self-research, external product business development, and pharmaceutical acquisitions [1] - Efforts will be made to optimize organizational structure, reduce labor costs, control expenses based on budgets, and centralize production to save costs and improve performance in the pharmaceutical sector [1]